INC Research Names Garth Tierney Executive Vice President, Asia/Pacific

Raleigh, N.C., and Port Adelaide, South Australia, Feb 28, 2013 - (ACN Newswire) - INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process(R) for delivering reliable results, today announced the promotion of Garth Tierney to Executive Vice President, Asia/Pacific responsible for driving the strategic development and overall growth of the Company's Asia/Pacific clinical research operations. Tierney, who served previously as the Company's Regional General Manager, Australia and Southeast Asia, co-founded Trident Clinical Research, an Australian-based CRO acquired by INC Research in 2011 after 14 years of operation.

"INC Research is experiencing tremendous opportunity to help drug developers navigate the diverse and complex landscape of conducting trials across the Asia/Pacific region, especially as many countries are poised to significantly increase their investment in clinical research," said Tierney. "This is an exciting time within this developing region and I look forward to helping our customers leverage the benefits of Asia/Pacific to advance their clinical development programs."

Prior to founding and managing Trident Clinical Research, Tierney worked for eight years in the clinical research industry in various senior management and operational management roles across several companies, including a global CRO, an Australian pharmaceutical company and two global pharmaceutical companies. He holds a graduate diploma in business administration and a Bachelor of Science in pharmacology from the University of Adelaide and the University of New South Wales, respectively, and worked in hypertension research for several years before joining the pharmaceutical industry. During this time, he published various papers and won the Whelan prize (awarded by ASCEPT). 

Tierney succeeds Kelvin Logan, PhD, who will retire in April. Dr. Logan joined INC Research in 2002 as the Company's first employee outside of North America and played an instrumental role in growing the EMEA and Asia/Pacific regions to 2,200 staff and 43 offices, helping to catapult INC Research into one of the top global CROs that has retained its strong global focus. 

"Asia/Pacific is a key focus area for INC Research because our customers are demanding a strong partner for on-the-ground expertise to help design and execute custom research programs. Garth is the obvious choice to take over the helm in the region based on his extensive knowledge and operational prowess," said COO Alistair Macdonald. "Additionally, I'd like to personally thank Kelvin for all of his tremendous accomplishments in building the Company's Asia/Pacific operations into what they are today."

INC Research provides Phase I to IV clinical development services in the Asia/Pacific region with extensive coverage across China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand and New Zealand. The Company has the broad regional presence, therapeutic expertise, operational excellence and ability to apply international insights to local projects to meet the needs of drug developers. For more information, visit the website for more information on INC Research's clinical trial services and experience in the region.

About INC Research

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical developmentprograms of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The Company's Trusted Process(R) methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit or follow us at @inc_research.

Contact: Lori Dorer, Media +1-513-345-1685

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: INC RESEARCH, LLC via Thomson Reuters ONE

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.